Nasdaq · Healthcare

PRECISION BIOSCIENCES INC (DTIL)

As-reported financials and recent SEC filings for PRECISION BIOSCIENCES INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$34.3M

Net income

$-45.7M

Net margin

-133.4%

Diluted EPS

$-3.56

ROE

-49.6%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$34.3M	$68.7M	$48.7M	$25.1M	$115.5M
Gross profit	—	—	—	—	—
Operating income	$-52.1M	$-26.2M	$-43.7M	$-62.3M	$-39.4M
Net income	$-45.7M	$7.2M	$-61.3M	$-111.6M	$-30.6M
Diluted EPS	$-3.56	$1.04	$-15.96	$-38.10	$-10.40

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-07-01

8-K2026-06-16

42026-06-05

42026-06-05

42026-06-05

42026-06-05

42026-06-05

42026-06-03

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on DTIL

Search PRECISION BIOSCIENCES INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.